BRAIN Biotech announces buy-out of minorities, new continental European production site, and expansion of its Baking Application Center
- Breatec B.V. is now fully owned by BRAIN Biotech AG following a minority buyout
- New and enlarged production site will open close to Eindhoven, NL
- Expanded competence centre for enzyme-based baking applications
ZWINGENBERG, Germany, May 20, 2025 – BRAIN Biotech, a leading provider of integrated solutions for the biologisation of industry, is pleased to announce that it has bought out the remaining minority shares in its Dutch subsidiary Breatec B.V.. With the closure of this transaction, all businesses in the BRAINBiocatalysts division are now fully owned by BRAIN Biotech AG.
Coinciding with this share purchase was the signing of a lease contract for a new site in the Netherlands. The search for a new site had been ongoing due to the commercial successes and rapidly increasing sales volumes, particularly in the flour and bakery enzymes business. The new site will have a significantly larger footprint and is again situated in the south of the Netherlands next to the major city of Den Bosch, conveniently located alongside the main A59 highway. The new site will operate as an integrated continental European production and warehousing hub. In addition, the company will also re-establish a test laboratory for baked goods there. An expanded competence centre for enzyme-based baking applications will promote customer intimacy and thus the joint development of new customer products.
